Loading...
•
Mar 31, 2024
Liquidia Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024.
Key Takeaways
Liquidia Corporation reported a revenue of $3.0 million for Q1 2024, compared to $4.5 million in Q1 2023. The net loss was $40.9 million, or $0.54 per share, compared to a net loss of $11.7 million, or $0.18 per share, for the same period in the prior year. Cash and cash equivalents totaled $157.9 million as of March 31, 2024, compared to $83.7 million as of December 31, 2023.
Removed all legal barriers for FDA to issue final action on the amended NDA for YUTREPIA.
Progressing the ASCENT study of YUTREPIA in PH-ILD.
Continuing to treat PAH and PH-ILD patients with L606.
Awaiting ruling from District Court on preliminary injunction in new patent infringement lawsuit filed by United Therapeutics.
Liquidia
Liquidia
Liquidia Revenue by Segment
Revenue by Segment
Promotion Agreement Revenue
CapyFin.com Forward Guidance
The company awaits the court's decision on a preliminary injunction motion filed by United Therapeutics and continues to enroll patients in the ASCENT study of YUTREPIA in PH-ILD.